We assessed the prevalence and phenotypic characteristics of extended-spectrum ␤-lactamase (ESBL) producers among cefuroxime-resistant (CXM-R) (MIC > 32 g/ml) members of the family Enterobacteriaceae in our institution. The 438 CXM-R clinical isolates obtained from nonurine sources among inpatients were screened. ESBL production was confirmed by disk diffusion assay using cefpodoxime (CPD), cefotaxime (CTX), and ceftazidime (CTZ) with and without clavulanate (CLAV). A difference of >5 mm in the size of the zone of inhibition in the presence of CLAV for at least one of the agents was considered representative of the ESBL phenotype: 186 isolates (42.5%) were confirmed as ESBL producers. The isolates tested and the rates of ESBL producers were as follows: Klebsiella spp. (n ‫؍‬ 81), 79%; Proteus spp. (n ‫؍‬ 58), 62%; Escherichia coli (n ‫؍‬ 64), 53%; Enterobacter spp. (n ‫؍‬ 69), 42%; Serratia spp. (n ‫؍‬ 70), 14%; Citrobacter spp. (n ‫؍‬ 25), 24%; Providencia spp. (n ‫؍‬ 21), 24%; Morganella spp. (n ‫؍‬ 41), 5%; and Kluyvera (n ‫؍‬ 3), 0%. The overall sensitivity of isolated ESBL confirmatory tests was 79% for CPD-CLAV, 66% for CTZ-CLAV, and 91% for CTX-CLAV. Sensitivities of CTZ-CLAV confirmatory tests for Klebsiella spp., Proteus spp., E. coli, and Enterobacter spp. were 84, 22, 76, and 62%, respectively, and those for CTX-CLAV were 95, 97, 94, and 83%, respectively. They were 90% for CPD-CLAV and CTZ-CLAV, 95% for CPD-CLAV and CTX-CLAV, and 100% for CTZ-CLAV and CTX-CLAV. ESBL production was highly prevalent among Enterobacteriaceae. Using resistance to CXM as an ESBL screening criterion is a suitable option in high-incidence areas where Klebsiella spp. are not the dominant ESBL producers. This screening criterion may simplify the screening test and improve its sensitivity, although at the price of testing more isolates. The CTX-CLAV combination confirmed ESBL producers better than the CTZ-CLAV combination, with sensitivity varying between species. Combined CTZ-CLAV and CTX-CLAV testing detected all these strains; CPD-CLAV provided no additional benefit.
Production of plasmid-mediated extended-spectrum ␤-lactamases (ESBLs) has emerged as an important mechanism of resistance to ␤-lactam antibiotics among members of the family Enterobacteriaceae (10) . Over 100 such enzymes, which differ in genotype and substrates affinities, have been described to date (see http://www.lahey.org/studies/webt.htm). Several lines of evidence have suggested that the production of ESBL has an important clinical impact. Studies on the inoculum effect (8) , animal experiment data (18) , and limited clinical data (3, 11, 13 ; L. B. Rice, J. D. C. Yao, K. Klimm, G. M. Eliopoulos, and R. C. Moellering, Jr., Letter, Antimicrob. Agents Chemother. 35:1243-1244, 1991) have raised the possibility that using cephalosporins and penicillins to treat infections caused by ESBLproducing organisms may result in adverse treatment outcomes (15) . Detection of ESBL producers poses a special challenge for clinical microbiology laboratories: although ESBL producers are able to hydrolyze extended-spectrum penicillins, cephalosporins, and aztreonam, the MICs of some and perhaps even all of these agents may be within the susceptible range.
Identification of ESBL producers by clinical laboratories is based on their phenotypic characteristics, i.e., the presence of an increased MIC of extended-spectrum cephalosporins and reduction in the MIC in the presence of a beta-lactamase inhibitor (9) . Since these tests are expensive and time-consuming, the National Committee for Clinical Laboratory Standards (NCCLS) has recommended that these specialized tests be performed based on screening criteria which include an elevated MIC of one of few cephalosporins and/or aztreonam. The NCCLS guide recommends that ESBL producers be reported as resistant to all penicillins and cephalosporins as well as to aztreonam, even when they are shown to be susceptible to these agents by conventional tests (12) . These guidelines refer specifically to Klebsiella pneumonia, Klebsiella oxytoca, and Escherichia coli. Indeed, clinical attention has focused on the occurrence of ESBLs among these genera, the ones most likely to be ESBL producers in the United State (19) . However, ESBL producers have been found in many other genera, including other members of the family Enterobacteriaceae, such as Citrobacter, Enterobacter, Morganella, Proteus, Providencia, Salmonella, and Serratia species (2) .
ESBLs are widespread all over the world, but the prevalence and phenotypic characteristics among clinical isolates may vary between geographical areas (19) . In this study, we aimed to systematically examine the prevalence of ESBL producers among members of the Enterobacteriaceae family in our institution, to characterize their phenotypes, and to evaluate the diagnostic tests that are used to detect ESBL production.
MATERIALS AND METHODS
Setting and study design. The Tel-Aviv Sourasky Medical Center is a 1,200-bed tertiary-care university-affiliated hospital located in central Israel. The clinical microbiology laboratory is ISO 9002 certified and processes over 85,000 clinical cultures annually. All gram-negative bacteria isolated during the study period were identified to the species level, and their susceptibilities to various antibiotics-including cefuroxime (CXM), cefotaxime (CTX), ceftazidime (CTZ), cefepime, and aztreonam-were determined by means of an automated identification and microdilution system using an overnight panel (Microscan; Dade International Inc., West Sacramento, Calif.). The results were recorded and interpreted according to NCCLS guidelines (12) .
The bacterial isolates selected for this study included 438 clinical nonurine isolates, all members of the family Enterobacteriaceae for which the MIC of CXM is Ն32 g/ml. They were collected at convenient times during a 9-month period (April 2000 to December 2000) and stored at Ϫ70°C in brain heart infusion containing 10% glycerol until further workup.
ESBL detection tests were based on the Kirby-Bauer disk diffusion test methodology (1) . For determining the ESBL phenotype, the zones of inhibition of each isolate were tested on Mueller-Hinton agar plates (Hy-Labs, Rehovot, Israel) using disks containing 30 g of cefpodoxime (CPD), CTX, and CTZ, either alone or in combination with 10 g of clavulanic acid (catalogue numbers: CT1612B, CT407B, CT1629B, CT1596B, CT1598B, and CT1597B, respectively; Oxoid, Hampshire, England). An organism was classified as having an ESBL producer phenotype if the zone of inhibition differed by Ն5 mm between at least one of the combination disks and its corresponding standard antibiotic disk. E. coli ATCC 25922 and K. pneumoniae ATCC 700603 were used daily as negative and positive controls for ESBL production, respectively. The sensitivity of each agent to detect an ESBL phenotype was determined relative to all agents in combination.
Based upon these results, the percentage of ESBL producers for a given species was calculated by multiplying the percentage of isolates with an ESBL phenotype among CXM-resistant isolates of the same species by the percentage of CXM-resistant isolates among nonurine hospital isolates of the same species.
RESULTS

Prevalence of ESBL-producing strains.
A total of 438 CXMresistant members of the family Enterobacteriaceae were studied (51 blood isolates and 387 from pus, wounds, or sputum). The isolates were tested by using the three combination disks, and 186 isolates (42.5%) were confirmed as being ESBL producers ( Performance of screening tests. The MICs for all hospital isolate members of the family Enterobacteriaceae were determined for CTX, CTZ, and aztreonam. For all hospital isolates that are CXM susceptible (or intermediate susceptible), the MICs of each of these agents was Ͻ2 g/ml. Of the 438 CXMresistant isolates, the MIC of CTX for 278 (63.5%) was Ն2 g/ml, the MIC of CTZ for 246 (56.2%) was Ն2 g/ml, and the MIC of aztreonam for 236 (53.9%) was Ն2 g/ml. Among the isolates confirmed to have an ESBL producer phenotype, for 15 (8%) the MIC of CTX was Ͻ2 g/ml, for 41 (22%) the MIC of CTZ was Ͻ2 g/ml, and for 31 (16.7%) the MIC of aztreonam was Ͻ2 g/ml. The distributions according to genera are presented in Table 2 . The respective sensitivities, specificities, and negative predictive values for screening CXM-resistant isolates with each agent were 91.9, 57.5, and 90.6% for CTX; 78, 59.9, and 51.7% for CTZ; and 83.3, 67.9, and 84.7% for aztreonam. Among the ESBL-producing strains, for 9 the MICs of aztreonam and CTX were Ͻ2 g/ml, for 27 the MICs of aztreonam and CTZ were Ͻ2 g/ml, for 8 the MICs of both CTX and CTZ were Ͻ2 g/ml, and for 7 the MICs of all three agents were Ͻ2 g/ml.
Confirmatory tests. The performance of each of three confirmatory tests (i.e., CPD, CTX, and CTZ with and without clavulanate) to detect an ESBL phenotype among members of the family Enterobacteriaceae was evaluated in comparison to the performance of all three in combination. The overall sensitivities of the tests were 79% for CPD with and without clavulanate, 66% for CTZ with and without clavulanate, and 91% for CTX with and without clavulanate. We also evaluated the performance of using two combination disks as a confirmatory test: combining CPD and CTZ (each with and without clavulanate) resulted in a test sensitivity of 90%, combining CPD with CTX resulted in 95% sensitivity, and combining CTZ with CTX resulted in 100% sensitivity.
The performance of the ESBL confirmatory tests in each of the four major ESBL producer genera in our institution was evaluated (Table 3) . Confirmatory tests based on CTX were more sensitive for each genus examined than were the tests based on CTZ or CPD. This was most prominent in confirming ESBL production among Proteus spp.
DISCUSSION
We sought to assess the prevalence and phenotypic characteristics of ESBL producers among CXM-resistant members of the family Enterobacteriaceae in our institution. Our findings revealed overall high prevalence. We found isolates that expressed an ESBL producer phenotype among every genus that was tested, with the exception of Kluyvera spp., of which only few isolates were available for testing. The prevalence among genera varied, with rates ranging between 35% among Klebsiella spp. and Proteus sp. isolates and from 12 to 22% for all other genera (except for Morganella spp., which expressed an ESBL phenotype in 4.5% of the isolates). Thus, in contrast to the attention paid mostly to ESBLs in E. coli and Klebsiella spp., our results pointed to the ESBL producer phenotype as being common in our institution among the various members of the family Enterobacteriaceae: it was equally prevalent among Proteus spp. and Klebsiella spp., and its occurrence in most other genera was at least within the same high range as in E. coli.
The prevalence of strains expressing the ESBL phenotype may vary across geographical regions (5, 16, 17, 19) . Most previous studies had focused on K. pneumoniae, and high rates of ESBL production have been reported among strains in Latin America (45%), Italy (37%), in New York City, N.Y. (44%) (16, 19) . However, the overall rate of CTZ resistance in the United States as a whole, as stated in the Centers for Disease Control and Prevention Project ICARE report, is 8% (6). This discrepancy emphasizes the great geographical diversity of ESBL occurrence even within one country, as well as the difficulty in presenting comprehensive data on this issue.
We elected to use the SENTRY data (19) for comparing the prevalence of ESBL production in our area to that reported in other geographical areas. The rates of the ESBL producer phenotype were higher in our center than those in the SEN-TRY report: our respective prevalence of ESBL phenotype in Klebsiella species, Proteus species, and E. coli were 35, 35, and 12%, while those in Latin America were 45, 22, and 8.5%; those in the Western Pacific region were 25, 1.8, and 7.9%; those in Europe were 23, 11, and 5.3%; and those in the United States were 7.6, 5, and 3.3%.
The NCCLS recommendations at the time of the present study were to screen for ESBL production in E. coli and Klebsiella spp. using the criterion of an MIC of one of the following five agents of Ն2 g/ml: CPD, CTZ, aztreonam, CTX, or ceftriaxone (12) . We evaluated the performance of conducting screening with CTZ, aztreonam, and CTX and found considerable differences between the agents. Specifically, for 15 (8%) of the isolates with an ESBL producer phenotype the MIC of CTX was Ͻ2 g/ml, for 41 (22%) the MIC of CTZ was Ͻ2 g/ml, and for 31 (16.7%) the MIC of aztreonam was Ͻ2 g/ml. Thus, CTX had the highest negative predictive value (91%) in our hospital. Using the criterion of an elevated MIC as being indicative of ESBL to any of the three agents would have detected all 64 ESBL-producing Klebsiella species, but seven isolates that were members of other genera which had an ESBL producer phenotype would have been missed. When resistance to CXM was added to the screening criteria, sensitivity for the detection of ESBLs improved to 100%.
Advantages of screening that uses criteria of CXM resistance. Screening that uses criteria of CXM resistance has several advantages. (i) Monitoring of CXM resistance is more feasible than continuously monitoring the MICs of several agents for multiple genera. (ii) It improves the negative predictive value for genera other than Klebsiella species. (iii) No isolates for which the MIC of any of the extended spectrum cephalosporins was Ն2 g/ml occurred among CXM-susceptible isolates in our study. Using this screening criterion, how- ever, will increase the number of isolates that will be selected for confirmatory testing. Nevertheless, we believe that this screening criterion is a suitable option in high-incidence areas where Klebsiella spp. are not the dominant ESBL producers. We evaluated three agents for the use in ESBL confirmatory testing. Overall, CTX performed best in detecting ESBL producers. Its superiority was most apparent for confirming ESBL production in Proteus species, probably as a result of the existence of ESBLs with high affinity to this agent. In contrast to our results, Winokur et al. reported that CTZ appeared to be a better reagent for detecting an ESBL than ceftriaxone (19) . This discrepancy might be due to differences in dominant enzymes in various geographical areas.
Our results demonstrate the importance of adapting the diagnostic tests for ESBL detection to a particular geographical area, a particular hospital, and particular genera. Moreover, we believe that these tests need to be evaluated periodically, given that their performance may change with the introduction of new enzymes.
Note that by being based on phenotypic testing, the tests we conducted may have shown false-negative results due to the coexistence of chromosomal beta-lactamases (4, 7) or to the presence of plasmid-mediated enzymes that are not inhibited by beta-lactamase inhibitors (5, 14) . In addition, it is very likely that the particular enzymes harbored by the tested organisms might influence test performance.
This systematic assessment of diagnostic tests aimed at detecting an ESBL phenotype among members of the Enterobacteriaceae revealed a high incidence of this phenotype among various genera in our institution. It also highlighted the need for local evaluation of the tests chosen in a particular setting as well as the need for guidelines for ESBL testing of species other than E. coli and Klebsiella spp.
